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Abstract Pluripotent stem cells are undi¡erentiated cells that
are capable of di¡erentiating to all three embryonic germ layers
and their di¡erentiated derivatives. They are transiently found
during embryogenesis, in preimplantation embryos and fetal go-
nads, or as established cell lines. These unique cell types are
distinguished by their wide developmental potential and by their
ability to be propagated in culture inde¢nitely, without loosing
their undi¡erentiated phenotype. This short review intends to
give a general overview on the pluripotent nature of embryo-
derived stem cells with a focus on human embryonic stem
cells.  2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Pluripotent stem cell lines, embryonic stem (ES), germ (EG)
and carcinoma (EC) cells, are undi¡erentiated cell lines that
are capable of forming virtually any cell type in the body.
Their wide developmental potential and unlimited life span
in culture make them extremely interesting and important
for basic and applied research. They can undergo di¡erentia-
tion in vivo and in vitro, allowing them to be used for the
study of basic processes in developmental biology. Moreover,
they can be genetically manipulated and could potentially be
used as a renewable cell source for restoring tissue function by
cell engineering and transplantation. It is possible to charac-
terize them by a distinct repertoire of cell-speci¢c markers,
including the presence of certain antigens, enzymes and the
expression of a number of developmentally regulated genes.
However, neither of these markers is completely restricted to
this type of cells. The following review intends to summarize
the accumulated information on the pluripotent nature of
embryo-derived stem cell lines, and discuss possible mecha-
nisms and functional molecules by which pluripotency is ac-
quired and maintained in these unique cell types.
2. The origin and properties of pluripotent cells
Pluripotent stem cells are transiently present during embry-
onic development, in preimplantation embryos (zygote to
morula and inner cell mass (ICM) of blastocyst) and in fetal
gonads (primordial germ cells (PGC)) [1]. They can also be
maintained as established cell lines, derived either from the
inner cell mass of blastocysts (embryonic stem (ES) cells)
[2,3], from primordial germ cells (embryonic germ (EG) cells)
[4,5], or from tumorigenic derivatives of germinal tissues (em-
bryonic carcinoma (EC) cells) [6] (Fig. 1). The embryo-derived
stem cell lines are considered to be pluripotent according to
several criteria (Fig. 1, box). They can develop into a wide
range of cell types in vitro and in vivo, and are immortal, can
be propagated inde¢nitely in culture while maintaining their
undi¡erentiated phenotype.
EC, ES and EG have been well characterized in mouse, and
are also available in human [7^10]. They are characterized by
a unique repertoire of cell surface molecules, including stage-
speci¢c embryonic antigens (SSEA), and the activity of spe-
ci¢c enzymes, such as alkaline phosphatase and telomerase
(summarized in [11,12]). Although neither of these markers
is completely cell speci¢c, their presence as a group is associ-
ated with the undi¡erentiated state of the cells. In addition, a
short list of molecular markers, which are rapidly down-regu-
lated upon di¡erentiation is available for mouse ES cells. It
includes several transcription factors like Rex1 [13], Genesis
[14], GBX2 [15], Oct4 [16], UTF2 [17], Pem [18] and L17 [19],
which are members of well-known gene families and that are
also expressed by the ICM of the blastocyst. Unfortunately,
none of them is exclusively expressed by pluripotent cells and
can be found in other cell types in the soma.
3. Developmental potential of pluripotent cells
Comparison of the di¡erentiation potential of murine ES,
EG and EC cells has shown that although these cells have
similar properties, their di¡erent origins are often re£ected
in various developmental potentials. EC cells, for example,
have a more restricted potential ; they are unlikely to be trans-
mitted through the germ line of chimeric animals and often
have karyotype abnormalities [20]. EG cells easily undergo
spontaneous di¡erentiation, but may be unable to support
normal development due to epigenetic modi¢cations which
have occurred during the formation of PGCs [21]. Thus, ES
cells were shown to have the greatest developmental potential,
di¡erentiating into the widest range of cell types (reviewed in
[22]). This chapter will focus on the recent ¢ndings that sup-
port the wide developmental potential of human ES cells. The
pluripotent nature of human ES cells can be demonstrated in
vitro and in vivo. In vitro, di¡erentiation may be triggered if
the cells aggregate by growing in suspension culture [23].
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These cell aggregates are called embryoid bodies, and mimic
to some extent the process of early embryonic development.
By day 20 in suspension culture di¡erent types of di¡erenti-
ated cells can be obtained spontaneously, shown either at the
level of RNA or protein (see Fig. 2 and [23^33]). Moreover, it
is possible to somewhat direct the di¡erentiation of the cells
into speci¢c cell types by treatment with growth factors
[24,33]. So far, human ES cells were shown to di¡erentiate
in vitro into about dozen of di¡erent cell types. Alternatively,
di¡erentiation may be induced by the expression of transcrip-
tion factors, which play a major role in early commitment of
cells into speci¢c lineages, as has been previously demon-
strated for mouse ES cells [34]. In vivo, by injecting the un-
di¡erentiated cells into nude mice, non-malignant tumors
(teratomas) are formed [8,10,35]. These tumors include
di¡erentiated derivatives of mesoderm, endoderm and ecto-
derm. Clearly, the most de¢nitive proof of pluripotency is
the ability of the cells to integrate, proliferate and di¡erentiate
to all cell lineages (including germ cells) by introducing them
into host blastocysts. This has been well practiced in the
mouse, where ES cells are genetically manipulated and deliv-
ered to host blastocysts for introducing germ line transmitted
genetic modi¢cations [36]. However, such experiments are un-
acceptable in human for obvious reasons. The ability to e⁄-
ciently direct the di¡erentiation of human ES cells and allow
the mass production of a speci¢c cell type in vitro, illustrates
their enormous potential as an unlimited cell source for trans-
plantation and their possible use as vectors in cell-based thera-
pies.
4. Stem cell selection
The potential of human embryonic stem cells to be used as
an unlimited cell source for cellular transplantation depends
on the availability of large and pure populations of undi¡er-
entiated cells, and on the ability to e⁄ciently direct their dif-
ferentiation into speci¢c cell types in vitro. In order to main-
tain pluripotency, the cells are grown under conditions which
support their undi¡erentiated growth and include the presence
of a feeder layer such as inactivated mouse embryonic ¢bro-
blasts (MEF). Murine ES cells were shown to be able to
sustain undi¡erentiated growth without a feeder layer in the
presence of LIF (leukemia inhibitory factor) [37,38]. Yet,
spontaneous di¡erentiation still occurs even under optimal
Fig. 1. Origin and derivation of human pluripotent stem cell lines. Pluripotent stem cells are derived either from the ICM, generating embry-
onic stem (ES) cells, from PGCs, generating embryonic germ (EG) cells, or from tumorigenic germinal tumors called teratomas, generating em-
bryonic carcinoma (EC) cells.
FEBS 26434 18-9-02 Cyaan Magenta Geel Zwart
R. Eiges, N. Benvenisty/FEBS Letters 529 (2002) 135^141136
conditions, especially in human cells [8,10]. It has been dem-
onstrated that the presence of di¡erentiating cells induces the
elimination of the pluripotent stem cells in culture, either by
forcing them to further di¡erentiate and/or by inducing apo-
ptosis [39]. Hence, by eliminating the di¡erentiated progeny, it
should be possible to facilitate their maintenance and obtain
uniform populations of undi¡erentiated cells. This can be
performed by introducing into the genome of ES cells a se-
lectable marker, such as the neomycin, under the regulation of
a pluripotent associated promoter sequence [39]. The undi¡er-
entiated cells express the neo resistance gene, which is turned
o¡ as the cells di¡erentiate, causing their immediate elimina-
tion by continuous G418 selection. Alternatively, the undi¡er-
entiated cells may be monitored in vitro and in vivo, by ex-
pressing the reporter gene green £uorescent protein (GFP),
under the control of promoters which are speci¢c to undi¡er-
entiated cells (such as the regulatory sequences of Oct4 or
Rex1). By tagging the undi¡erentiated cells with green £uo-
rescence, they can be analyzed and sorted according to the
intensity of their £uorescent emission using a £uorescent acti-
vating cell sorter (FACS) [40]. This allows obtaining pure
populations of undi¡erentiated cells, which can be re-plated
and propagated or be used for further analysis. In addition,
this system may be considered for eliminating undi¡erentiated
cells prior to transplantation, avoiding the risk of tumor in-
duction.
5. Functional molecules
Research in mouse ES cells has elucidated two unrelated
molecular pathways, the LIF and the Oct4 pathways, that
play a role in maintaining pluripotency and supporting undif-
ferentiated growth (Fig. 3). It has been shown that LIF sup-
ports undi¡erentiated proliferation of ES and EG cells by
binding to the gp130-LIF receptor heterodimer and activating
the STAT3 transcription factor (reviewed in [41]). Yet, in vivo
studies of knockout mice show that the maintenance of plu-
ripotency in the embryo does not rely on the gp130 signaling
pathway but only under suboptimal conditions of delayed
implantation [42]. LIF3=3 embryos develop to term and are
fertile [43] while LIFR3=3 and gp1303=3 embryos die late in
gestation (12.5^18.5 dpc) or shortly after birth [46^48].
Fig. 2. Developmental potential of human ES cells in vitro. Spontaneous and induced di¡erentiation of human ES cell results in the generation
of terminally di¡erentiated cells of ectoderm, mesoderm and endoderm origin in culture. In parentheses are references [10,23^33] to manuscripts
demonstrating in vitro di¡erentiation of human ES cells into the di¡erent cell types.
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STAT33=3 embryos, however, develop until the egg cylinder
stage (7 dpc) and rapidly degenerate with no obvious meso-
derm [49]. In addition, it seems that LIF is not active in
supporting undi¡erentiated growth of human ES cells in cul-
ture [8,10]. These ¢ndings support the existence of alternative
pathways, which operate in sustaining self-renewal.
Oct4, which is a POU-V-related DNA binding transcription
factor, has been shown to be associated with the phenotype of
totipotent/pluripotent cells in mice (reviewed in [51]). It is ex-
pressed by all pluripotent cells during embryogenesis and is
also abundantly expressed by ES, EG and EC cell lines
[52,53]. Knockout mice de¢cient in Oct4 develop only to the
blastocyst stage [16]. They are unable to produce any di¡er-
entiated derivatives other than trophoblast cells and as a con-
sequence, are absorbed shortly after implantation. These re-
sults demonstrate that Oct4 is required for preventing somatic
di¡erentiation of the ICM and is crucial for maintaining the
undi¡erentiated state during embryonic development. Fur-
thermore, in vitro manipulation of Oct4 expression in ES cells
shows that it is the relative amount of the protein, as com-
Fig. 3. Functional molecules and related pathways associated with pluripotency. Two unrelated molecular pathways, LIF and Oct4, are associ-
ated with the maintenance of pluripotency and self-renewal of ES cells in mice. A table and a schematic illustration summarize the phenotypic
e¡ects of knockout mice, that have been produced for each molecule that is known to be directly involved in either the Oct4 or the LIF path-
way [15,42^50,52,53].
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pared to other transcription factors, that ultimately deter-
mines cell fate [54]. Therefore, even though both LIF and
Oct4 pathways may be involved in controlling pluripotency,
the molecular mechanisms and the genes that govern them
remain, as yet, largely unknown.
6. Search for pluripotent associated genes
There is only little information regarding the genes which
are directly associated with pluripotency. In fact, Oct4 is the
only gene that has been shown to be involved in vivo in the
maintenance of the undi¡erentiated state of cells. The search
for additional genes which are speci¢c to all pluripotent cells
will allow to further investigate their unique developmental
potential and study the mechanisms by which pluripotency
is maintained. The search for genes, which are exclusively ex-
pressed by pluripotent cells, could be performed by comparing
closely related populations of undi¡erentiated and di¡erenti-
ated cells, i.e. the ICM and trophectoderm of early stage
blastocysts. Identi¢cation of di¡erentially expressed genes in
preimplantation embryos is technically di⁄cult due to the
limited amount of biological material, but has been previously
performed by two-dimensional protein analysis [55] and PCR-
based enriched methods [56,57], resulting in the identi¢cation
of only a limited number of genes. Recently, a large-scale
cDNA sequencing analysis, based on the collection of over
25 000 ESTs from preimplantation embryos, was reported
[58]. Stage-speci¢c cDNA libraries from unfertilized oocytes,
zygotes, 2-cell, 4-cell, 8-cell, morula and early blastocysts were
constructed and compared to available database. Based on
sequence similarity searches, over 9700 unique genes were
identi¢ed. Half of them were found to be novel, supporting
the impression that many of the genes which are expressed by
preimplantation embryos have not yet been characterized.
Many (about 17%) were suggested to be stage speci¢c and
only about 0.1% show constitutive expression throughout pre-
implantation development. An alternative approach would be
to compare ES to their immediate di¡erentiated derivatives,
simple EBs, bypassing the problem of limited amount of cells
available for analysis. This has been practiced in an e¡ort to
identify downstream genes of Oct4 through the use of a sup-
pression-subtractive hybridization method, resulting in the
identi¢cation of new genes which may have a role in the
establishment or maintenance of pluripotency in mouse cells
[59]. Furthermore, it should be possible to perform large-scale
cDNA comparisons by the use of microarrays, allowing ge-
nome-wide expression pro¢ling of these unique cells.
7. Cell reprogramming
The recent advancements in the derivation of human pluri-
potent stem cell lines and the success in mammalian embryo
cloning by nuclear transfer (NT), provide an attractive possi-
bility for restoring tissue function by cellular transplantation
through therapeutic cloning. In this method a nucleus from a
somatic cell of a patient is introduced into an enucleated
oocyte and allowed to develop in vitro to the blastocyst stage.
Such NT-derived blastocysts may be used for the establish-
ment of perfectly matched ES cell lines that can be induced to
di¡erentiate in vitro and provide the patient with an autolo-
gous graft. Although sophisticated, therapeutic cloning is not
unreasonable as it has been previously demonstrated to be
feasible in mice [60,61]. Yet, before this procedure can be
considered for clinical application it should be determined
how well can a somatic nuclear be reprogrammed without
being transmitted through the germ line.
Although embryo cloning by somatic cell NT has been suc-
cessfully achieved in several mammalian species, e⁄ciencies
are still low due to embryonic lethality and increased inci-
dence of malformations among ¢rst generation viable o¡-
spring. It has been speculated that nuclei from adult and
advanced stage embryos could not be fully reprogrammed
by the ooplasm. Even though X inactivation was shown to
occur properly in somatic cell-derived cloned mice [62], it
remains to be determined how complete is this process by
examining additional markers that are liable to epigenetic
modi¢cations during embryonic development. Indeed, subtle
abnormalities in expression and methylation of several im-
printed genes were shown to occur in NT-derived cloned
mice [63]. Yet, viable o¡spring survives to adulthood despite
the widespread dysregulation in expression of these genes. It
has been suggested that the somatic clones fail to re-activate
key embryonic genes, such as Oct4 for example, during pre-
implantation and early postimplantation development and
therefore are incapable of forming embryonic lineages [64].
However, since cell transplantation therapy by embryo clon-
ing does not require full-term embryonic development but
rather the formation of blastocysts and the di¡erentiation of
only speci¢c cell types, it may be su⁄cient. An alternative
approach suggested for obtaining autologous ES cell lines is
to induce de-di¡erentiation through the insertion of a somatic
nucleus into the cytoplasm of a pluripotent stem cell, bypass-
ing the problematic step of embryo cloning. In order to under-
stand whether pluripotent cell lines can reverse gene re-pro-
gramming and restore pluripotency, hybrids between
undi¡erentiated EC, EG or ES cells and fully di¡erentiated
cells were examined. The hybrid cells show a loss of stage- and
tissue-speci¢c markers of the somatic cell parent (gene extinc-
tion) and de novo activation of traits and genes which are
characteristic to pluripotent cells [21,65,66]. X inactivation,
for example, is a process that is tightly linked with di¡eren-
tiation and occurs in the soma of females. By demonstrating
the re-activation of X following cell fusion and it’s random
inactivation during di¡erentiation, it was possible to prove
that pluripotent stem cells can reset the inactivation mark
correctly. Furthermore, when induced to di¡erentiate, either
in vitro or in vivo, a wide spectrum of di¡erentiated cells
could be obtained. The hybrid cells can also be examined
for their developmental potential by injecting them into host
blastocysts. By generating viable chimeras, it was possible to
show cell hybrids in di¡erent tissues, indicating their ability to
contribute to all cell lineages. It remains to be further inves-
tigated how pluripotency is maintained, lost and restored dur-
ing cell commitment and di¡erentiation, tumorigenesis, game-
togenesis and embryo cloning.
8. Conclusions
Pluripotent stem cells are undi¡erentiated cells that have
the potential to develop into all cell types in the body. They
are transiently present in the embryo and are available as
embryo-derived established cell lines. Their pluripotent char-
acter, as determined by their ability to form all embryonic
germ layers and their di¡erentiated derivatives in vitro and
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in vivo, has made them an extremely interesting and impor-
tant cell source for basic and applied research, especially for
cell-based therapy and the study of early embryonic develop-
ment. They can be manipulated in vitro, by controlling their
growth conditions or by introducing genetic modi¢cations
into them, allowing to direct their di¡erentiation into speci¢c
cell types or to monitor and select for them during growth in
culture. However, since the mechanisms by which these cells
acquire such a wide developmental potential and remain un-
di¡erentiated are yet largely unknown, it remains to be dis-
covered what are the functional molecules and how do they
operate in sustaining self-renewal and maintain pluripotency.
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